SBI Securities’s Acurx Pharmaceuticals ACXP Stock Holding History

SBI Securities’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9	Hold	6	–	–	﹤0.01%	3927
2026 Q1	$22	Sell	6 -7	-54%	-$20	﹤0.01%	3741
2025 Q4	$32	Hold	13	–	–	﹤0.01%	3673
2025 Q3	$56	Sell	13 -1	-7%	-$6	﹤0.01%	3677
2025 Q2	$145	Hold	14	–	–	﹤0.01%	3418
2025 Q1	$111	Hold	14	–	–	﹤0.01%	3409
2024 Q4	$220	Buy	+14	New	+$422	﹤0.01%	3203

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

SBI Securities's ACXP Position: Q2 2026 in Review

SBI Securities held its Acurx Pharmaceuticals (ACXP) position steady in Q2 2026 at 6 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #3927.

SBI Securities first reported a position in ACXP in Q4 2024 and has held it in 7 quarters since. The position peaked at $220 in Q4 2024. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

SBI Securities held 6 shares of Acurx Pharmaceuticals worth $9 as of Q2 2026.
SBI Securities left its Acurx Pharmaceuticals share count unchanged in Q2 2026.
Acurx Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3927 holding.
SBI Securities first reported a position in Acurx Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Acurx Pharmaceuticals position peaked at $220 in Q4 2024.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.